The lead drug in Alexion’s $930M buyout deal last fall just flopped — adding injury to analysts’ M&A insults
When Alexion $ALXN put down $930 million in cash last fall to buy Achillion, the biotech’s top execs were particularly proud of 2 clinical-stage assets, with a spotlight on the lead drug danicopan (ACH-4471) in Phase II. That drug, along with a companion therapy in Phase I, fit right in their R&D wheelhouse, noted CEO Ludwig Hantson.
But now the lead drug, redubbed ALXN2040, is being washed out and repositioned after failing 2 Phase II trials for C3 Glomerulopathy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.